Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

FACTORS INFLUENCING LONG-TERM SURVIVAL AFTER HOSPITALIZATION WITH PNEUMOCOCCAL PNEUMONIA.

Ruiz LA, Serrano L, España PP, Martinez-Indart L, Gómez A, Uranga A, Castro S, Artaraz A, Zalacain R.

J Infect. 2019 Nov 5. pii: S0163-4453(19)30338-X. doi: 10.1016/j.jinf.2019.10.024. [Epub ahead of print]

PMID:
31704242
2.

Community-Acquired Pneumonia Patients at Risk for Early and Long-term Cardiovascular Events Are Identified by Cardiac Biomarkers.

Menéndez R, Méndez R, Aldás I, Reyes S, Gonzalez-Jimenez P, España PP, Almirall J, Alonso R, Suescun M, Martinez-Dolz L, Torres A.

Chest. 2019 Aug 2. pii: S0012-3692(19)31392-3. doi: 10.1016/j.chest.2019.06.040. [Epub ahead of print]

PMID:
31381883
3.

Evolution of serotypes in bacteremic pneumococcal adult pneumonia in the period 2001-2014, after introduction of the pneumococcal conjugate vaccine in bizkaia (spain).

España PP, Uranga A, Ruiz LA, Quintana JM, Bilbao A, Aramburu A, Serrano L, Ayarza R, Martinez AP, Zalacain R.

Vaccine. 2019 Jun 27;37(29):3840-3848. doi: 10.1016/j.vaccine.2019.05.052. Epub 2019 May 29.

PMID:
31153692
4.

Initial Inflammatory Profile in Community-acquired Pneumonia Depends on Time since Onset of Symptoms.

Méndez R, Menéndez R, Cillóniz C, Amara-Elori I, Amaro R, González P, Posadas T, Gimeno A, España PP, Almirall J, Torres A.

Am J Respir Crit Care Med. 2018 Aug 1;198(3):370-378. doi: 10.1164/rccm.201709-1908OC.

5.

Predicting 1-year mortality after hospitalization for community-acquired pneumonia.

Uranga A, Quintana JM, Aguirre U, Artaraz A, Diez R, Pascual S, Ballaz A, España PP.

PLoS One. 2018 Feb 14;13(2):e0192750. doi: 10.1371/journal.pone.0192750. eCollection 2018.

6.

Long-term Mortality in Community-acquired Pneumonia.

Uranga A, España PP.

Arch Bronconeumol. 2018 Aug;54(8):412-413. doi: 10.1016/j.arbres.2017.12.019. Epub 2018 Feb 7. English, Spanish. No abstract available.

7.

The burden of PCV13 serotypes in hospitalized pneumococcal pneumonia in Spain using a novel urinary antigen detection test. CAPA study.

Menéndez R, España PP, Pérez-Trallero E, Uranga A, Méndez R, Cilloniz C, Marimón JM, Cifuentes I, Méndez C, Torres A.

Vaccine. 2017 Sep 18;35(39):5264-5270. doi: 10.1016/j.vaccine.2017.08.007. Epub 2017 Aug 18.

PMID:
28823622
8.

Age-related differences in management and outcomes in hospitalized healthy and well-functioning bacteremic pneumococcal pneumonia patients: a cohort study.

Ruiz LA, España PP, Gómez A, Bilbao A, Jaca C, Arámburu A, Capelastegui A, Restrepo MI, Zalacain R.

BMC Geriatr. 2017 Jun 20;17(1):130. doi: 10.1186/s12877-017-0518-0.

9.

Duration of Antibiotic Treatment in Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial.

Uranga A, España PP, Bilbao A, Quintana JM, Arriaga I, Intxausti M, Lobo JL, Tomás L, Camino J, Nuñez J, Capelastegui A.

JAMA Intern Med. 2016 Sep 1;176(9):1257-65. doi: 10.1001/jamainternmed.2016.3633.

PMID:
27455166
10.

Performance of pro-adrenomedullin for identifying adverse outcomes in community-acquired pneumonia.

España PP, Capelastegui A, Mar C, Bilbao A, Quintana JM, Diez R, Esteban C, Bereciartua E, Unanue U, Uranga A.

J Infect. 2015 May;70(5):457-66. doi: 10.1016/j.jinf.2014.12.003. Epub 2014 Dec 11.

PMID:
25499199
11.

Pneumococcal pneumonia: differences according to blood culture results.

Capelastegui A, Zalacain R, Bilbao A, Egurrola M, Iturriaga LA, Quintana JM, Gomez A, Esteban C, España PP.

BMC Pulm Med. 2014 Aug 5;14:128. doi: 10.1186/1471-2466-14-128.

12.

Streptococcus pneumoniae antigen in urine: diagnostic usefulness and impact on outcome of bacteraemic pneumococcal pneumonia in a large series of adult patients.

Zalacain R, Capelastegui A, Ruiz LA, Bilbao A, Gomez A, Uranga A, España PP.

Respirology. 2014 Aug;19(6):936-43. doi: 10.1111/resp.12341. Epub 2014 Jun 26.

13.

Bacteremic pneumococcal pneumonia in elderly and very elderly patients: host- and pathogen-related factors, process of care, and outcome.

Ruiz LA, Zalacain R, Capelastegui A, Bilbao A, Gomez A, Uranga A, España PP.

J Gerontol A Biol Sci Med Sci. 2014 Aug;69(8):1018-24. doi: 10.1093/gerona/glt288. Epub 2014 Jan 27.

PMID:
24470128
14.

Utility of two biomarkers for directing care among patients with non-severe community-acquired pneumonia.

España PP, Capelastegui A, Bilbao A, Diez R, Izquierdo F, Lopez de Goicoetxea MJ, Gamazo J, Medel F, Salgado J, Gorostiaga I, Quintana JM; Population Study of Pneumonia (PSoP) Group.

Eur J Clin Microbiol Infect Dis. 2012 Dec;31(12):3397-405. doi: 10.1007/s10096-012-1708-5. Epub 2012 Aug 5.

PMID:
23010902
15.

Etiology of community-acquired pneumonia in a population-based study: link between etiology and patients characteristics, process-of-care, clinical evolution and outcomes.

Capelastegui A, España PP, Bilbao A, Gamazo J, Medel F, Salgado J, Gorostiaga I, Lopez de Goicoechea MJ, Gorordo I, Esteban C, Altube L, Quintana JM; Poblational Study of Pneumonia (PSoP) Group.

BMC Infect Dis. 2012 Jun 12;12:134. doi: 10.1186/1471-2334-12-134.

16.

The International Community-Acquired Pneumonia (CAP) Collaboration Cohort (ICCC) study: rationale, design and description of study cohorts and patients.

Myint PK, Kwok CS, Majumdar SR, Eurich DT, Clark AB, España PP, Man SY, Huang DT, Yealy DM, Angus DC, Capelastegui A, Rainer TH, Marrie TJ, Fine MJ, Loke YK.

BMJ Open. 2012 May 21;2(3). pii: e001030. doi: 10.1136/bmjopen-2012-001030. Print 2012.

17.

Score to identify the severity of adult patients with influenza A (H1N1) 2009 virus infection at hospital admission.

Capelastegui A, Quintana JM, Bilbao A, España PP, Garin O, Alonso J, Astray J, Cantón R, Castilla J, Castro A, Delgado-Rodríguez M, Godoy P, Gónzález-Candelas F, Martín V, Mayoral JM, Pumarola T, Tamames S, Soldevila N, Baricot M, Domínguez A; CIBERESP Cases and Controls in Pandemic Influenza Working Group, Spain.

Eur J Clin Microbiol Infect Dis. 2012 Oct;31(10):2693-701. Epub 2012 Apr 24.

PMID:
22526871
18.

The health, activity, dyspnea, obstruction, age, and hospitalization: prognostic score for stable COPD patients.

Esteban C, Quintana JM, Aburto M, Moraza J, Arostegui I, España PP, Aizpiri S, Capelastegui A.

Respir Med. 2011 Nov;105(11):1662-70. doi: 10.1016/j.rmed.2011.05.005. Epub 2011 Jun 23.

19.

Study of community-acquired pneumonia: incidence, patterns of care, and outcomes in primary and hospital care.

Capelastegui A, España PP, Bilbao A, Gamazo J, Medel F, Salgado J, Gorostiaga I, Esteban C, Altube L, Gorordo I, Quintana JM; Poblational Study of Pneumonia (PSoP) Group.

J Infect. 2010 Nov;61(5):364-71. doi: 10.1016/j.jinf.2010.07.015. Epub 2010 Aug 6.

PMID:
20692290
20.

Validation and comparison of SCAP as a predictive score for identifying low-risk patients in community-acquired pneumonia.

España PP, Capelastegui A, Quintana JM, Bilbao A, Diez R, Pascual S, Esteban C, Zalacaín R, Menendez R, Torres A.

J Infect. 2010 Feb;60(2):106-13. doi: 10.1016/j.jinf.2009.11.013. Epub 2009 Dec 2. Review.

PMID:
19961875
21.

Impact of hospitalisations for exacerbations of COPD on health-related quality of life.

Esteban C, Quintana JM, Moraza J, Aburto M, Egurrola M, España PP, Pérez-Izquierdo J, Aguirre U, Aizpiri S, Capelastegui A.

Respir Med. 2009 Aug;103(8):1201-8. doi: 10.1016/j.rmed.2009.02.002. Epub 2009 Mar 9.

22.

Development of a prognostic index for 90-day mortality in patients discharged after admission to hospital for community-acquired pneumonia.

Capelastegui A, España PP, Quintana JM, Bilbao A, Menendez R, Zalacain R, Torres A.

Thorax. 2009 Jun;64(6):496-501. doi: 10.1136/thx.2008.098814. Epub 2009 Feb 22.

PMID:
19237392
23.

Declining length of hospital stay for pneumonia and postdischarge outcomes.

Capelastegui A, España PP, Quintana JM, Gallarreta M, Gorordo I, Esteban C, Urrutia I, Bilbao A.

Am J Med. 2008 Oct;121(10):845-52. doi: 10.1016/j.amjmed.2008.05.010.

PMID:
18823851
24.

Predictors of mortality in patients with stable COPD.

Esteban C, Quintana JM, Aburto M, Moraza J, Egurrola M, España PP, Pérez-Izquierdo J, Capelastegui A.

J Gen Intern Med. 2008 Nov;23(11):1829-34. doi: 10.1007/s11606-008-0783-x. Epub 2008 Sep 16.

25.

Pneumonia: criteria for patient instability on hospital discharge.

Capelastegui A, España PP, Bilbao A, Martinez-Vazquez M, Gorordo I, Oribe M, Urrutia I, Quintana JM.

Chest. 2008 Sep;134(3):595-600. doi: 10.1378/chest.07-3039. Epub 2008 May 19.

PMID:
18490403
26.

[Longitudinal incidence of tuberculosis in a cohort of contacts: factors associated with the disease].

Salinas C, Capelastegui A, Altube L, España PP, Díez R, Oribe M, Urrutia I, Aguirre U.

Arch Bronconeumol. 2007 Jun;43(6):317-23. Spanish.

27.

Development and validation of a clinical prediction rule for severe community-acquired pneumonia.

España PP, Capelastegui A, Gorordo I, Esteban C, Oribe M, Ortega M, Bilbao A, Quintana JM.

Am J Respir Crit Care Med. 2006 Dec 1;174(11):1249-56. Epub 2006 Sep 14.

PMID:
16973986
28.

[Evaluation of clinical practice in patients admitted with community-acquired pneumonia over a 4-year period].

Capelastegui A, España PP, Quintana JM, Gorordo I, Sañudo C, Bilbao A.

Arch Bronconeumol. 2006 Jun;42(6):283-9. Spanish.

29.

Validation of a predictive rule for the management of community-acquired pneumonia.

Capelastegui A, España PP, Quintana JM, Areitio I, Gorordo I, Egurrola M, Bilbao A.

Eur Respir J. 2006 Jan;27(1):151-7.

30.

[Patients hospitalized with community-acquired pneumonia: a comparative study of outcomes by medical specialty area].

Capelastegui A, España PP, Quintana JM, Gorordo I, Martínez Urquiri A, Idoiaga I, Bilbao A.

Arch Bronconeumol. 2005 Jun;41(6):300-6. Review. Spanish.

31.

Management of community-acquired pneumonia and secular trends at different hospitals.

Capelastegui A, España PP, Quintana JM, Gorordo I, Gallardo MS, Idoiaga I, Bilbao A.

Respir Med. 2005 Mar;99(3):268-78.

32.

Improvement of process-of-care and outcomes after implementing a guideline for the management of community-acquired pneumonia: a controlled before-and-after design study.

Capelastegui A, España PP, Quintana JM, Gorordo I, Ortega M, Idoiaga I, Bilbao A.

Clin Infect Dis. 2004 Oct 1;39(7):955-63. Epub 2004 Sep 8.

PMID:
15472846
33.

Drug-resistant pneumococcal pneumonia: clinical relevance and related factors.

Aspa J, Rajas O, Rodríguez de Castro F, Blanquer J, Zalacain R, Fenoll A, de Celis R, Vargas A, Rodríguez Salvanés F, España PP, Rello J, Torres A; Pneumococcal Pneumonia in Spain Study Group.

Clin Infect Dis. 2004 Mar 15;38(6):787-98. Epub 2004 Mar 1.

PMID:
14999620
34.

A prediction rule to identify allocation of inpatient care in community-acquired pneumonia.

España PP, Capelastegui A, Quintana JM, Soto A, Gorordo I, García-Urbaneja M, Bilbao A.

Eur Respir J. 2003 Apr;21(4):695-701.

35.

[Diagnostic methods and treatment of community-acquired pneumonia in Spain: NACE study].

Celis MR, Torres A, Zalacaín R, Aspa J, Blanquer J, Blanquer R, Gallardo J, España PP; Grupo de trabajo del Area TIR para el estudio del diagnóstico y tratamiento de la NAC en España (NACE).

Med Clin (Barc). 2002 Sep 21;119(9):321-6. Spanish.

PMID:
12356360
36.

[The current state of substitution treatment in congenital emphysema due to alpha-1-antitrypsin deficiency. The report of the National Registry].

Miravitlles M, Vidal R, Barros-Tizón JC, Bustamante A, España PP, Casas F, Martínez MT, Escudero C, Jardí R.

Arch Bronconeumol. 1999 Oct;35(9):446-54. Review. Spanish. No abstract available.

PMID:
10596342
37.

Usefulness of a national registry of alpha-1-antitrypsin deficiency. The Spanish experience.

Miravitlles M, Vidal R, Barros-Tizón JC, Bustamante A, España PP, Casas F, Martínez MT, Escudero C, Jardi R.

Respir Med. 1998 Oct;92(10):1181-7.

Supplemental Content

Loading ...
Support Center